1.888.321.7828 sales@pepid.com

Timely Insights for Healthcare Experts 

Breakthrough Non-Drug ADHD Treatment Gets FDA Approval

Children living with attention hyperactivity disorder (ADHD) may soon experience non-pharmacologic relief through a breakthrough medical device. For children between the ages 7 and 12 and currently not on medication, the pocket-sized device works by delivering mild...

read more
CDC Update: E. Coli O103 Outbreak Is from Ground Beef

Update to PEPID Pulse “E. Coli O103 Outbreak Investigation in Five States” on April 5 , 2019 The CDC has narrowed the Shiga Toxin-producing Escherichia Coli (E. Coli) O103 outbreak to ground beef.  The total number of people infected has increased to 109 people...

read more
E. Coli O103 Outbreak Investigation in Five States

The CDC, several states, the U.S. Department of Agriculture’s Food Safety and Inspection Services, and the U.S. FDA are investigating a multistate outbreak of Shiga Toxin-producing Escherichia coli (E.Coli) O103 infections. There is not yet an identification of a...

read more
Cerner Endorses Adoption of Normative FHIR R4 Standard

Kansas-based EHR vendor Cerner proudly takes the industry lead in adopting HL7's latest rollout - FHIR Release 4, the normative interoperability standard. The vendor embraced FHIR R4 only 3 months after it was published. “It’s incredibly important that major vendors...

read more
FDA Approves Two New Oral Drugs to Treat Multiple Sclerosis

Mayzent (siponimod) The FDA approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Mayzent was shown to be...

read more
First Treatment for Post-partum Depression FDA Approved

Tuesday, March 19, the FDA approved Zulresso (brexanolone) injection for intravenous (IV) use to treat post-partum depression (PPD) in adult women. No other drug before now has been approved to specifically treat PPD. Zulresso will be available through Risk Evaluation...

read more